| Ytd | -21.89% | |
| 1y | 21.74% |
| Open | 4.09 | Prev Close | 4.09 | Low | 3.98 | High | 4.20 | Mkt Cap | 157.83M |
| Vol | 2.57K | Avg Vol | 723.14K | EPS | -1.34 | P/E | -3.05 | Forward P/E | -1.61 |
| Beta | 1.48 | Short Ratio | 14.46 | Inst. Own | 51.11% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 4.33 | 200-d Avg | 5.33 | 1yr Est | 26.40 |
TARA News
Protara Therapeutics (TARA) might move higher on growing optimism about its earnings prospects, whic
MIAMI, July 20, 2026 /PRNewswire/ -- Royal Caribbean Group (NYSE: RCL) today announced the appointme
NEW YORK--(BUSINESS WIRE)--Tradeweb Markets Inc. (Nasdaq: TW), a global leader in electronic trading
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-sta
Protara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial
Event will provide an overview of Lymphatic Malformations, the treatment landscape and the TARA-002
Protara Therapeutics Inc. (NASDAQ:TARA) reported updated 12-month Phase 2 data for TARA-002 in patie
TARA-002 demonstrates 72% complete response rate at any time, 67% complete response rate at the 6-mo
The Company intends to submit a Biologics License Application (BLA) for TARA-002 in Lymphatic Malfor
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-s
Protara Therapeutics, Inc. (NASDAQ: TARA - Get Free Report) was the recipient of a large increase in
Reported interim data from ADVANCED-2 trial in non-muscle invasive bladder cancer (NMIBC); TARA-002
Protara Therapeutics (NASDAQ: TARA) executives outlined progress across the company's two clinical-s
Protara Therapeutics, Inc. (TARA) Discusses Interim Phase II Results for TARA-002 in Non-Muscle Inva
Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse event
NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-st
NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara” or
NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-st
Protara Therapeutics, Inc. (NASDAQ: TARA - Get Free Report) has been given an average rating of "Mod
Protara Therapeutics, Inc. (TARA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcri
On Tuesday, 647 companies set new 52-week lows.
On Monday, 369 companies set new 52-week lows.
Tuesday's session saw 211 companies set new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
Tuesday's session saw 729 companies set new 52-week lows.